Outcomes of Aortic Valve Replacement for Chronic Aortic Insufficiency: Analysis of the Society of Thoracic Surgeons Database.
Journal
The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
09
12
2020
revised:
08
04
2021
accepted:
12
04
2021
pubmed:
29
4
2021
medline:
9
4
2022
entrez:
28
4
2021
Statut:
ppublish
Résumé
This study evaluated outcomes and risk factors for surgical aortic valve replacement (SAVR) for aortic insufficiency (AI) in a national cohort. We analyzed the incidence, outcomes, and risk factors for SAVR for AI in the Society of Thoracic Surgeons Adult Cardiac Surgery Database. The national database was queried for patients with moderate or greater AI undergoing isolated SAVR between July 2011 and December 2018. Patients with moderate or greater aortic stenosis, acute dissection, active endocarditis, concomitant procedures, or emergent operation were excluded. AI was staged using guideline criteria based on symptoms and ventricular remodeling. Operative mortality and morbidity were compared between stages, and risk factors for operative death were identified. A total of 12,564 patients underwent isolated SAVR for AI from 2011 to 2018. Patients were most frequently AI stage D (7019 [57.5%]), compared with B (1405 [11.2%]), C1 (1128 [9.0%]), or C2 (1325 [10.5%]). Operative mortality was 1.1% overall, and increased between stage C1, C2, and D (0.4% vs 0.7% vs 1.6%, respectively, P < .01), along with major morbidity (5.1% vs 7.5% vs 9.9%, respectively; P < .01). Mortality was higher in patients with severe ventricular dilation and an ejection fraction of less than 0.30 (2.7% vs 1.0%, P < .01). Risk factors for death were symptomatic AI, decreased ejection fraction, age, weight, body surface area, and dialysis. Operative mortality and morbidity for isolated SAVR for AI is very low in a national cohort, providing a benchmark for future transcatheter approaches. Operative risk increases with advanced ventricular remodeling. SAVR before development of ventricular remodeling may be appropriate in patients with severe AI.
Sections du résumé
BACKGROUND
This study evaluated outcomes and risk factors for surgical aortic valve replacement (SAVR) for aortic insufficiency (AI) in a national cohort. We analyzed the incidence, outcomes, and risk factors for SAVR for AI in the Society of Thoracic Surgeons Adult Cardiac Surgery Database.
METHODS
The national database was queried for patients with moderate or greater AI undergoing isolated SAVR between July 2011 and December 2018. Patients with moderate or greater aortic stenosis, acute dissection, active endocarditis, concomitant procedures, or emergent operation were excluded. AI was staged using guideline criteria based on symptoms and ventricular remodeling. Operative mortality and morbidity were compared between stages, and risk factors for operative death were identified.
RESULTS
A total of 12,564 patients underwent isolated SAVR for AI from 2011 to 2018. Patients were most frequently AI stage D (7019 [57.5%]), compared with B (1405 [11.2%]), C1 (1128 [9.0%]), or C2 (1325 [10.5%]). Operative mortality was 1.1% overall, and increased between stage C1, C2, and D (0.4% vs 0.7% vs 1.6%, respectively, P < .01), along with major morbidity (5.1% vs 7.5% vs 9.9%, respectively; P < .01). Mortality was higher in patients with severe ventricular dilation and an ejection fraction of less than 0.30 (2.7% vs 1.0%, P < .01). Risk factors for death were symptomatic AI, decreased ejection fraction, age, weight, body surface area, and dialysis.
CONCLUSIONS
Operative mortality and morbidity for isolated SAVR for AI is very low in a national cohort, providing a benchmark for future transcatheter approaches. Operative risk increases with advanced ventricular remodeling. SAVR before development of ventricular remodeling may be appropriate in patients with severe AI.
Identifiants
pubmed: 33910050
pii: S0003-4975(21)00730-X
doi: 10.1016/j.athoracsur.2021.04.027
pmc: PMC8542644
mid: NIHMS1697318
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
763-772Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL152280
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL139430
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Références
J Am Coll Cardiol. 2016 Nov 15;68(20):2144-2153
pubmed: 27855803
Ann Thorac Surg. 2018 Jul;106(1):8-13
pubmed: 29937221
J Am Coll Cardiol. 1984 May;3(5):1118-26
pubmed: 6707364
J Am Coll Cardiol. 2007 Apr 3;49(13):1465-71
pubmed: 17397676
Cardiology. 2018;141(3):132-140
pubmed: 30517917
JACC Cardiovasc Imaging. 2008 Jan;1(1):1-11
pubmed: 19356398
Cardiol Clin. 1995 Feb;13(1):73-83, 85
pubmed: 7796434
J Am Coll Cardiol. 1997 Sep;30(3):746-52
pubmed: 9283535
Circulation. 2018 Jan 9;137(2):184-196
pubmed: 29311349
Heart. 2018 May;104(10):835-840
pubmed: 29092919
Ann Thorac Surg. 2019 Dec;108(6):1625-1632
pubmed: 31654621
Ann Thorac Surg. 2009 Jul;88(1 Suppl):S23-42
pubmed: 19559823
Ann Thorac Surg. 2018 May;105(5):1419-1428
pubmed: 29577924
Eur Heart J. 2003 Jul;24(13):1231-43
pubmed: 12831818
Ann Thorac Surg. 2010 Mar;89(3):677-82
pubmed: 20172107
Circulation. 2009 Sep 15;120(11 Suppl):S134-8
pubmed: 19752358
Circulation. 2014 Jun 10;129(23):2440-92
pubmed: 24589852
Ann Thorac Surg. 2017 Apr;103(4):1222-1228
pubmed: 27863733
Stat Med. 2000 May 15;19(9):1141-64
pubmed: 10797513
Ann Thorac Surg. 2016 Jul;102(1):41-7
pubmed: 27016840